Replies to post #134595 on Biotech Values

[turtlepower]

In that case wouldn't NVS be a candidate to buyout IDIX? One interesting aspect of the craze for nucs is that NVS passed on 184 (considered similar to INX 189) 2 years ago.
http://ir.idenix.com/releasedetail.cfm?ReleaseID=611093

Either way they would want a return on their investment so they would let someone else purchase IDIX or they would develop 184 on their own at a much faster pace.